Latest Breaking News On - First approved therapy - Page 1 : comparemela.com

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U S FDA

CASTRES, France, May 20, 2024 /PRNewswire/ Pierre Fabre Laboratories today announce the submission by Atara Biotherapeutics (ATARA), a leader in T-cell

United statesMidi pyréesPierre fabreAdriana herreraLaurence marchalPierre fabre pharmaceuticals incDrug administrationFirst allogeneict cell therapyTab cel wouldFirst approved therapyPierre fabre pharmaceuticalsPierre fabre laboratoriesBiologics license applicationChief executive officerPierre fabre medical careLaboratories media contact

STEALTH BIOTHERAPEUTICS BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION

STEALTH BIOTHERAPEUTICS BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesAnna stallmannAustin murtaghReenie mccarthyAnna stallmann communicationsStealth biotherapeutics incDrug administrationBarth syndromeCardioskeletal diseaseAffects approximatelyElamipretide would becomeFirst approved therapyNew drug applicationPriority reviewOrphan drugFast track

Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich s Ataxia

Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich s Ataxia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn hunterWendy segalExchange commissionReata pharmaceuticals incEuropean commissionDrug administrationWall streetNeuromuscular diseaseAffects approximatelyOmaveloxolone would becomeFirst approved therapyPriority reviewNew drug applicationFast track designationRare pediatric disease designation